Literature DB >> 19896548

Cancer associated fibroblasts in cancer pathogenesis.

Omar E Franco1, Aubie K Shaw, Douglas W Strand, Simon W Hayward.   

Abstract

In the past century, gradual but sustained advances in our understanding of the molecular mechanisms involved in the growth and invasive properties of cancer cells have led to better management of tumors. However, many tumors still escape regulation and progress to advanced disease. Until recently, there has not been an organized and sustained focus on the "normal" cells in the vicinity of tumors. Interactions between the tumor and these host cells, as well as autonomous qualities of the host cells themselves, might explain why tumors in people with histologically similar cancers often behave and respond differently to treatment. Cells of the tumor microenvironment, variously referred to as cancer stroma, reactive stroma or carcinoma-associated fibroblasts (CAF), exist in close proximity to the cancer epithelium. Both stromal and epithelial phenotypes co-evolve during tumorigenesis and it is now becoming clear that these stromal cells may not be the innocent bystanders they had been widely thought to be, but rather may be active contributors to carcinogenesis. Our group and others have shown the important role that CAF play in the progression of cancer. In this article we will address current trends in the study of the interactions between cancer stroma and tumor cells in different organs. We will also highlight perceived knowledge gaps and suggest research areas that need to be further explored to provide new targets for anticancer therapies. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19896548      PMCID: PMC2823834          DOI: 10.1016/j.semcdb.2009.10.010

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  65 in total

1.  Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells.

Authors:  Akinobu Maeda; Koh-ichi Nakashiro; Shingo Hara; Toyokazu Sasaki; Yoshihiro Miwa; Nozomu Tanji; Masayoshi Yokoyama; Hiroyuki Hamakawa; Ryoichi Oyasu
Journal:  Biochem Biophys Res Commun       Date:  2006-07-17       Impact factor: 3.575

2.  Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model.

Authors:  Jennifer A Tuxhorn; Stephanie J McAlhany; Feng Yang; Truong D Dang; David R Rowley
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

3.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.

Authors:  Keisuke Kurose; Kristie Gilley; Satoshi Matsumoto; Peter H Watson; Xiao-Ping Zhou; Charis Eng
Journal:  Nat Genet       Date:  2002-10-15       Impact factor: 38.330

4.  In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas.

Authors:  Chenzhong Kuang; Yan Xiao; Xubao Liu; Teresa M Stringfield; Shaobo Zhang; Zhenzhen Wang; Yan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-27       Impact factor: 11.205

5.  Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets.

Authors:  Koichi Fukino; Lei Shen; Satoshi Matsumoto; Carl D Morrison; George L Mutter; Charis Eng
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

Review 6.  Prostate cancer and the met hepatocyte growth factor receptor.

Authors:  Beatrice S Knudsen; Magnus Edlund
Journal:  Adv Cancer Res       Date:  2004       Impact factor: 6.242

7.  Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.

Authors:  Mingfang Ao; Omar E Franco; Dean Park; Dayanidhi Raman; Karin Williams; Simon W Hayward
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

8.  Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Authors:  X Li; V Placencio; J M Iturregui; C Uwamariya; A-R Sharif-Afshar; T Koyama; S W Hayward; N A Bhowmick
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

9.  Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.

Authors:  A F Olumi; G D Grossfeld; S W Hayward; P R Carroll; T D Tlsty; G R Cunha
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

Review 10.  Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation.

Authors:  Catherine M Kolf; Elizabeth Cho; Rocky S Tuan
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  155 in total

1.  Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2.

Authors:  Sonia Alcolea; Rosa Antón; Mercedes Camacho; Marta Soler; Arantzazu Alfranca; Francesc-Xavier Avilés-Jurado; Juan-Miguel Redondo; Miquel Quer; Xavier León; Luis Vila
Journal:  J Lipid Res       Date:  2012-02-04       Impact factor: 5.922

2.  Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.

Authors:  M A Frassanito; L Rao; M Moschetta; R Ria; L Di Marzo; A De Luisi; V Racanelli; I Catacchio; S Berardi; A Basile; E Menu; S Ruggieri; B Nico; D Ribatti; R Fumarulo; F Dammacco; K Vanderkerken; A Vacca
Journal:  Leukemia       Date:  2013-09-02       Impact factor: 11.528

Review 3.  A review on myricetin as a potential therapeutic candidate for cancer prevention.

Authors:  Nazia Afroze; Sreepoorna Pramodh; Arif Hussain; Madiha Waleed; Kajal Vakharia
Journal:  3 Biotech       Date:  2020-04-24       Impact factor: 2.406

Review 4.  Tumor angiogenesis: molecular pathways and therapeutic targets.

Authors:  Sara M Weis; David A Cheresh
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

5.  Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor.

Authors:  Julie Lecomte; Anne Masset; Silvia Blacher; Ludovic Maertens; André Gothot; Marie Delgaudine; Françoise Bruyère; Oriane Carnet; Jenny Paupert; Martin Illemann; Jean-Michel Foidart; Ida K Lund; Gunilla Høyer-Hansen; Agnes Noel
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

Review 6.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

7.  Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Damanzoopinder Samrao; Grace Kim; Kate Lawrenson; Teodulo Meneses; Song Liu; Annie Yessaian; Tanja Pejovic
Journal:  Cancer Microenviron       Date:  2013-11-10

8.  Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency In Vivo.

Authors:  Hisataka Kitano; Yoh Masaoka; Atsushi Mamiya; Yusuke Fujiwara; Toshio Miki; Chiaki Hidai
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 9.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 10.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.